Bill Lands
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bill Lands has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
D. Bibus
Lipid Technologies, LLC and The Center for Spirituality and Healing, The University of Minnesota, Austin, MN 55912, USA
1 shared publicationDoug Bibus
Community Faculty, University of Minnesota Center for Spirituality and Healing, and Lipid Technologies LLC, P.O. Box 216, Austin, MN 55912, United States
1 shared publication- Etienne Lamoreaux
Computer Specialist, NIAAA, NIH, 5635 Fishers Lane, Bethesda, MD, 20892-8304, USA
1 shared publication - Joseph R. Hibbeln
Department of Psychiatry, Barton Health, South Lake Tahoe, California, USA
1 shared publication - Ken D. Stark
Department of Kinesiology and Health Sciences, University of Waterloo, Waterloo, ON N2L 3G1, Canada
1 shared publication - Sarah E. Strandjord
Seattle Children's Hospital for Pediatrics, USA
1 shared publication
Latest Publications
- Open Access
- 30 June 2022
- Published by Scientific Archives
- Vol. 4 (3) , 92-94
A Nonagenarian’s View of Dietary Impacts on Cellular Immunology
Lands B. A Nonagenarian’s View of Dietary Impacts on Cellular Immunology. J Cell Immunol. 2022;4(3):92-94.
- 30 June 2022
- Published by Scientific Archives
- Vol. 4 (3) , 92-94
Open AccessA Nonagenarian’s View of Dietary Impacts on Cellular Immunology
Lands B. A Nonagenarian’s View of Dietary Impacts on Cellular Immunology. J Cell Immunol. 2022;4(3):92-94.
- Open Access
- 1 January 2022
- Published by Elsevier in Progress in Lipid Research
- Vol. 85, 101142
Lipid nutrition: “In silico” studies and undeveloped experiments
- 1 January 2022
- Published by Elsevier in Progress in Lipid Research
- Vol. 85, 101142
Open AccessLipid nutrition: “In silico” studies and undeveloped experiments
- Open Access
- 1 September 2018
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 136, 15-21
Dynamic interactions of n-3 and n-6 fatty acid nutrients
- 1 September 2018
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 136, 15-21
Open AccessDynamic interactions of n-3 and n-6 fatty acid nutrients
- Open Access
- 1 November 2017
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 133, 4-10
Highly unsaturated fatty acids (HUFA) mediate and monitor food’s impact on health
- 1 November 2017
- Published by Elsevier in Prostaglandins & Other Lipid Mediators
- Vol. 133, 4-10
Open AccessHighly unsaturated fatty acids (HUFA) mediate and monitor food’s impact on health
- Open Access
- 13 July 2016
- Published by Springer Nature in Drug Safety
- Vol. 39 (9) , 787-799
Benefit–Risk Assessment of Fish Oil in Preventing Cardiovascular Disease
Cardiovascular disease (CVD) is a preventable disease, which combines two general processes: chronic vascular inflammation and acute thrombosis. Both are amplified with positive feedback signals by n-6 eicosanoids derived from food-based n-6 highly unsaturated fatty acids (n-6 HUFA). This amplification is lessened by competing actions of n-3 HUFA. Death results from fatal interactions of the vascular wall with platelets and clotting proteins. The benefits of fish oil interventions are confounded by complex details in pharmacokinetics, pharmacodynamics, adverse events, timescale factors, topology, financial incentives and people’s sense of cause and effect. Two basic aspects of n-3 HUFA that are overlooked in CVD dynamics are saturable, hyperbolic responses of the enzymes continually supplying n-6 HUFA and hard-to-control positive feedback receptor signals by excessive n-6 HUFA–based mediators. Multiple feedback loops in inflammation and thrombosis have diverse mediators, and reducing one mediator that occurs above its rate-limiting levels may not reduce the pathophysiology. Clinicians have developed some successful interventions that decrease CVD deaths in the form of secondary prevention. However, the current high CVD prevalence in the USA remains unchanged, and successful primary prevention of CVD remains uncertain. This review weighs the available evidence to help clinicians, the biomedical community and the public put the use of fish oil supplements into a balanced perspective.
- 13 July 2016
- Published by Springer Nature in Drug Safety
- Vol. 39 (9) , 787-799
Open AccessBenefit–Risk Assessment of Fish Oil in Preventing Cardiovascular Disease
Cardiovascular disease (CVD) is a preventable disease, which combines two general processes: chronic vascular inflammation and acute thrombosis. Both are amplified with positive feedback signals by n-6 eicosanoids derived from food-based n-6 highly unsaturated fatty acids (n-6 HUFA). This amplification is lessened by competing actions of n-3 HUFA. Death results from fatal interactions of the vascular wall with platelets and clotting proteins. The benefits of fish oil interventions are confounded by complex details in pharmacokinetics, pharmacodynamics, adverse events, timescale factors, topology, financial incentives and people’s sense of cause and effect. Two basic aspects of n-3 HUFA that are overlooked in CVD dynamics are saturable, hyperbolic responses of the enzymes continually supplying n-6 HUFA and hard-to-control positive feedback receptor signals by excessive n-6 HUFA–based mediators. Multiple feedback loops in inflammation and thrombosis have diverse mediators, and reducing one mediator that occurs above its rate-limiting levels may not reduce the pathophysiology. Clinicians have developed some successful interventions that decrease CVD deaths in the form of secondary prevention. However, the current high CVD prevalence in the USA remains unchanged, and successful primary prevention of CVD remains uncertain. This review weighs the available evidence to help clinicians, the biomedical community and the public put the use of fish oil supplements into a balanced perspective.
- Open Access
- 8 February 2016
- Published by Walter de Gruyter GmbH
- p. 117-136
7. Cholesterol: the most misunderstood marker
- 8 February 2016
- Published by Walter de Gruyter GmbH
- p. 117-136
Open Access7. Cholesterol: the most misunderstood marker
- Open Access
- 2 August 2015
- Published by Hindawi Limited in BioMed Research International
- Vol. 2015, 1-8
Omega-3 PUFAs Lower the Propensity for Arachidonic Acid Cascade Overreactions
A productive view of the benefits from omega-3 (n-3) nutrients is that the dietary essential omega-6 (n-6) linoleic acid has a very narrow therapeutic window which is widened by n-3 nutrients. The benefit from moderate physiological actions of the arachidonic acid cascade can easily shift to harm from excessive pathophysiological actions. Recognizing the factors that predispose the cascade to an unwanted overactivity gives a rational approach for arranging beneficial interactions between the n-3 and n-6 essential nutrients that are initial components of the cascade. Much detailed evidence for harmful cascade actions was collected by pharmaceutical companies as they developed drugs to decrease those actions. A remaining challenge is to understand the factors that predispose the cascade toward unwanted outcomes and create the need for therapeutic interventions. Such understanding involves recognizing the similar dynamics for dietary n-3 and n-6 nutrients in forming the immediate precursors of the cascade plus the more vigorous actions of the n-6 precursor, arachidonic acid, in forming potent mediators that amplify unwanted cascade outcomes. Tools have been developed to aid deliberate day-to-day quantitative management of the propensity for cascade overactivity in ways that can decrease the need for drug treatments.
- 2 August 2015
- Published by Hindawi Limited in BioMed Research International
- Vol. 2015, 1-8
Open AccessOmega-3 PUFAs Lower the Propensity for Arachidonic Acid Cascade Overreactions
A productive view of the benefits from omega-3 (n-3) nutrients is that the dietary essential omega-6 (n-6) linoleic acid has a very narrow therapeutic window which is widened by n-3 nutrients. The benefit from moderate physiological actions of the arachidonic acid cascade can easily shift to harm from excessive pathophysiological actions. Recognizing the factors that predispose the cascade to an unwanted overactivity gives a rational approach for arranging beneficial interactions between the n-3 and n-6 essential nutrients that are initial components of the cascade. Much detailed evidence for harmful cascade actions was collected by pharmaceutical companies as they developed drugs to decrease those actions. A remaining challenge is to understand the factors that predispose the cascade toward unwanted outcomes and create the need for therapeutic interventions. Such understanding involves recognizing the similar dynamics for dietary n-3 and n-6 nutrients in forming the immediate precursors of the cascade plus the more vigorous actions of the n-6 precursor, arachidonic acid, in forming potent mediators that amplify unwanted cascade outcomes. Tools have been developed to aid deliberate day-to-day quantitative management of the propensity for cascade overactivity in ways that can decrease the need for drug treatments.
- Open Access
- 1 August 2015
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 99, 19-23
Balancing proportions of competing omega-3 and omega-6 highly unsaturated fatty acids (HUFA) in tissue lipids
- 1 August 2015
- Published by Elsevier in Prostaglandins, Leukotrienes and Essential Fatty Acids
- Vol. 99, 19-23
Open AccessBalancing proportions of competing omega-3 and omega-6 highly unsaturated fatty acids (HUFA) in tissue lipids